Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $594 | $392 | $550 | $285 |
| Short-Term Investments | $0 | $0 | $0 | $231 |
| Receivables | $49 | $3 | $3 | $9 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $71 | $43 | $17 | $9 |
| Total Curr. Assets | $714 | $438 | $570 | $535 |
| Property Plant & Equip (Net) | $233 | $120 | $121 | $65 |
| Goodwill | $149 | $52 | $1 | $1 |
| Intangibles | $336 | $36 | $1 | $1 |
| Long-Term Investments | $6 | $0 | $0 | $0 |
| Tax Assets | $2 | $0 | $0 | $0 |
| Other NC Assets | $9 | $7 | $8 | $9 |
| Total NC Assets | $734 | $216 | $131 | $76 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,449 | $654 | $701 | $610 |
| Liabilities | – | – | – | – |
| Payables | $22 | $4 | $5 | $3 |
| Short-Term Debt | $22 | $6 | $6 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $62 | $36 | $57 | $10 |
| Other Curr. Liab. | $82 | $47 | $33 | $32 |
| Total Curr. Liab. | $187 | $93 | $100 | $47 |
| LT Debt | $86 | $45 | $45 | $10 |
| Deferred Rev, NC | $119 | $51 | $70 | $7 |
| Deferred Tax Liab, NC | $17 | $1 | $0 | $0 |
| Other NC Liab. | $5 | $0 | $0 | $4 |
| Total NC Liab. | $226 | $97 | $115 | $21 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $67 | $50 | $50 | $11 |
| Total Liabilities | $414 | $190 | $215 | $67 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,431 | -$968 | -$640 | -$400 |
| AOCI | -$8 | $0 | $0 | -$0 |
| Other Equity | $2,474 | $1,431 | $1,125 | $943 |
| Total Equity | $1,035 | $463 | $486 | $543 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,449 | $654 | $701 | $610 |
| Net Debt | -$486 | -$341 | -$499 | -$274 |